经典生酮饮食与加用抗癫痫药物在耐药性癫痫婴儿中的比较(KIWE):英国多中心开放标签随机临床试验
KIWE试验在英国19家医院纳入1-24月龄耐药性癫痫婴儿,随机分为经典生酮饮食组或加用抗癫痫药物组治疗8周。第6-8周每日发作中位数两组相似(生酮组5次 vs 药物组3次;IRR 1.33,95%CI 0.84-2.11)。严重不良事件两组相近(生酮组51% vs 药物组45%),生酮组有3例死亡,判定与治疗无关。
要点
- 经典生酮饮食与加用抗癫痫药物在减少婴儿期耐药性癫痫发作频率上无显著差异。
- 生酮饮食组与药物组严重不良事件发生率相近,最常见均为癫痫发作。
- 生酮饮食组报告3例死亡,经判定与治疗无关。
核心结论
- 在4期试验中,生酮饮食与加用抗癫痫药物在疗效和耐受性上无差异,在耐药性癫痫婴儿中似乎安全。
- 对于已尝试两种抗癫痫药物后仍发作的婴儿,生酮饮食可能是一种治疗选择。
研究设计与样本
- 4期、开放标签、多中心、随机临床试验,在英国19家医院招募1-24月龄耐药性癫痫婴儿。
- 耐药性癫痫定义为每周4次及以上发作且既往使用2种及以上抗癫痫药物。
- 经过1周或2周观察期后,使用计算机生成方案随机分配至经典生酮饮食组或加用抗癫痫药物组治疗8周。
- 主要结局为第6-8周记录的每日发作中位数,采用改良意向性分析。
- 计划随访至12个月,因招募缓慢和资金终止而提前终止。
主要发现
- 2015年1月1日至2021年9月30日,155名婴儿接受资格评估,136名符合标准并随机分配(男75名[55%],女61名[45%])。
- 生酮饮食组78例、抗癫痫药物组58例,第8周分别有61例和47例纳入改良意向性分析。
- 第6-8周每日发作中位数:生酮饮食组5次(IQR 1-16) vs 抗癫痫药物组3次(IQR 2-11),IRR 1.33(95%CI 0.84-2.11)。
- 至少发生一次严重不良事件的婴儿数:生酮饮食组40例(51%,共78例) vs 抗癫痫药物组26例(45%,共58例)。
- 试验期间3例婴儿死亡,均随机分配至生酮饮食组,经当地主要研究者和数据安全监察委员会判定与治疗无关。
临床怎么用
- 生酮饮食可能是已尝试两种抗癫痫药物后仍发作的婴儿的治疗选择。
局限性
- 因招募缓慢和资金终止,试验在所有参与者达到12个月随访前提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many infancy-onset epilepsies have poor prognosis for seizure control and neurodevelopmental outcome. Ketogenic diets can improve seizures in children older than 2 years and adults who are unresponsive to antiseizure medicines. We aimed to establish the efficacy of a classic ketogenic diet at reducing seizure frequency compared with further antiseizure medicine in infants with drug-resistant epilepsy. METHODS: In this phase 4, open-label, multicentre, randomised clinical trial, infants aged 1-24 months with drug-resistant epilepsy (defined as four or more seizures per week and two or more previous antiseizure medications) were recruited from 19 hospitals in the UK. Following a 1-week or 2-week observation period, participants were randomly assigned using a computer-generated schedule, without stratification, to either a classic ketogenic diet or a further antiseizure medication for 8 weeks. Treatment allocation was masked from research nurses involved in patient care, but not from participants. The primary outcome was the median number of seizures per day, recorded during weeks 6-8. All analyses were by modified intention to treat, which included all participants with available data. Participants were followed for up to 12 months. All serious adverse events were recorded. The trial is registered with the European Union Drug Regulating Authorities Clinical Trials Database (2013-002195-40). The trial was terminated early before all participants had reached 12 months of follow-up because of slow recruitment and end of funding. FINDINGS: Between Jan 1, 2015, and Sept 30, 2021, 155 infants were assessed for eligibility, of whom 136 met inclusion criteria and were randomly assigned; 75 (55%) were male and 61 (45%) were female. 78 infants were assigned to a ketogenic diet and 58 to antiseizure medication, of whom 61 and 47, respectively, had available data and were included in the modifified intention-to-treat analysis at week 8. The median number of seizures per day during weeks 6-8, accounting for baseline rate and randomised group, was similar between the ketogenic diet group (5 [IQR 1-16]) and antiseizure medication group (3 [IQR 2-11]; IRR 1·33, 95% CI 0·84-2·11). A similar number of infants with at least one serious adverse event was reported in both groups (40 [51%] of 78 participants in the ketogenic diet group and 26 [45%] of 58 participants in the antiseizure medication group). The most common serious adverse events were seizures in both groups. Three infants died during the trial, all of whom were randomly assigned a ketogenic diet: one child (who also had dystonic cerebral palsy) was found not breathing at home; one child died suddenly and unexpectedly at home; and one child went into cardiac arrest during routine surgery under anaesthetic. The deaths were judged unrelated to treatment by local principal investigators and confirmed by the data safety monitoring committee. INTERPRETATION: In this phase 4 trial, a ketogenic diet did not differ in efficacy and tolerability to a further antiseizure medication, and it appears to be safe to use in infants with drug-resistant epilepsy. A ketogenic diet could be a treatment option in infants whose seizures continue despite previously trying two antiseizure medications. FUNDING: National Institute for Health and Care Research.
引用
- Schoeler NE, Marston L, Lyons L, et al. Classic ketogenic diet versus further antiseizure medicine in infants with drug-resistant epilepsy (KIWE): a UK, multicentre, open-label, randomised clinical trial. Lancet Neurol. 2023. PMID: 37977712. doi:10.1016/S1474-4422(23)00370-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。